DSM Biologics has reached an agreement to acquire the assets and associated business of the Rhobust technology from Denmark-based Upfront Chromatography A/S for pharmaceutical and other applications. DSM Biologics will gain all rights for the commercialization of the Rhobust technology in various fields. The technology will lead to further innovation in the downstream processing for the manufacturing of recombinant proteins and antibodies, according to a DSM statement. DSM Biologics will cont...